trending Market Intelligence /marketintelligence/en/news-insights/trending/EEy-fFX938Kfw5f7jB-eNA2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

J&J gets expanded approval for psoriasis drug from US FDA

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


J&J gets expanded approval for psoriasis drug from US FDA

The U.S. Food and Drug Administration approved an expanded indication for Johnson & Johnson unit Janssen Biotech Inc.'s Stelara to treat moderate to severe plaque psoriasis in patients aged 12 years or older who are candidates for phototherapy or systemic therapy.

Psoriasis is a chronic, autoimmune inflammatory disorder that results in the overproduction of skin cells.

The approval of Stelara is based on data from a phase 3 study, where at least two-thirds of patients aged 12 years or older responded to the drug after just two doses.

Safety findings for adolescent patients treated with the drug were consistent with those seen in studies in adults with the disease.